Citigroup’s Ortho Clinical Diagnostics Holdings plc Ordinary Shares OCDX Stock Holding History

Citigroup’s Portfolio OCDX Stock Details OCDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-887,571	Closed	-$16.6M	–	6897
2022 Q1	$16.6M	Buy	887,571 +843,988	+1,937%	+$15.2M	0.01%	1030
2021 Q4	$933K	Buy	43,583 +22,882	+111%	+$451K	﹤0.01%	3329
2021 Q3	$382K	Buy	20,701 +9,665	+88%	+$195K	﹤0.01%	3798
2021 Q2	$236K	Sell	11,036 -762	-6%	-$15.5K	﹤0.01%	4162
2021 Q1	$228K	Buy	+11,798	New	+$208K	﹤0.01%	3947

Other funds holding OCDX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citigroup's OCDX Position: Q2 2022 in Review

Citigroup sold out of Ortho Clinical Diagnostics Holdings plc Ordinary Shares (OCDX) in Q2 2022, closing a stake of 887,571 shares — an estimated $16.6M sold.

Citigroup first reported a position in OCDX in Q1 2021 and held it in 5 quarters. The position peaked at $16.6M in Q1 2022. 1 fund tracked by Wall St. Rank holds OCDX as of Q2 2022.

Citigroup reported no remaining Ortho Clinical Diagnostics Holdings plc Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Citigroup sold 887,571 Ortho Clinical Diagnostics Holdings plc Ordinary Shares shares in Q2 2022, an estimated $16.6M.
Citigroup first reported a position in Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q1 2021 and held it in 5 quarters.
Citigroup's Ortho Clinical Diagnostics Holdings plc Ordinary Shares position peaked at $16.6M in Q1 2022.
1 fund tracked by Wall St. Rank held Ortho Clinical Diagnostics Holdings plc Ordinary Shares as of Q2 2022.

Based on Citigroup's 13F filing for Q2 2022, filed 10 Aug 2022.